We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov Menu

AdvisaTM IPG Clinical Evaluation Study

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2009 by Medtronic Bakken Research Center.
Recruitment status was:  Recruiting
ClinicalTrials.gov Identifier:
First Posted: February 9, 2009
Last Update Posted: February 24, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Medtronic Bakken Research Center
The purpose of the Advisa IPG clinical study is to evaluate the overall system safety and clinical performance of the Advisa DR Implantable Pulse Generator (IPG).

Condition Intervention
Bradycardia Atrial Tachyarrhythmia Device: Advisa IPG

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Clinical Study to Evaluate System Safety and Clinical Performance of the AdvisaTM IPG

Further study details as provided by Medtronic Bakken Research Center:

Primary Outcome Measures:
  • Confirm safety of the device by assessing the percentage of subjects with an unanticipated serious adverse device effect (USADE) at 1-month post-implant [ Time Frame: 1 month ]

Secondary Outcome Measures:
  • System performance as observed during Holter recordings, Save-to-Disk data and Technical Observations. [ Time Frame: 1 month ]

Estimated Enrollment: 80
Study Start Date: February 2009
Estimated Study Completion Date: June 2009
Estimated Primary Completion Date: April 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Advisa IPG
Device: Advisa IPG
Implantable Pulse Generator will be implanted

Detailed Description:

The Advisa IPG is an investigational dual chamber pacemaker that provides rate-responsive bradycardia pacing and diagnostics and atrial tachycardia detection and therapy.

The study will be a prospective, non-randomized, multicenter clinical study, conducted.

To allow for sufficient experience with the device, a maximum of 80 subjects may be implanted with the Advisa device. Data will be collected at baseline (enrollment), implant, 1-, 3- and 6- months post implant and every 6 months thereafter or until study closure (whichever occurs first), unscheduled follow-up visits, System Modifications, Technical Observations, Study Deviations, Study Exit, upon notification of new or updated Adverse Events and in case of death.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients who have an IPG indication for implantation of a dual chamber pacemaker.
  • Patients who are geographically stable and available for follow-up at the study center for the duration of the study.
  • Patients who have signed a Medical Ethics Committee (MEC) approved Informed Consent form.

Exclusion Criteria:

  • Patients with a life expectancy less than the duration of the study.
  • Patients with a Class III indication for permanent pacing according to ACC/AHA/NASPE 2002 guidelines.
  • Patients with medical conditions that preclude the testing required for all patients by the study protocol or that otherwise limit study participation required for all patients.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00839384

Contact: Advisa clinical study team advisa.brc@medtronic.com

Czech Republic
Hospital Recruiting
City, Czech Republic
Contact: Doctor Doctor, MD         
Principal Investigator: Doctor Doctor, MD         
Sponsors and Collaborators
Medtronic Bakken Research Center
Study Chair: Advisa Clinical Study Team Medtronic Bakken Research Center
  More Information

Responsible Party: CRDM CE Clinical Department, Medtronic Bakken Research Center
ClinicalTrials.gov Identifier: NCT00839384     History of Changes
Other Study ID Numbers: 114
First Submitted: February 6, 2009
First Posted: February 9, 2009
Last Update Posted: February 24, 2009
Last Verified: February 2009

Additional relevant MeSH terms:
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes